FNDC1 inhibitors represent a class of chemical compounds that specifically target the protein FNDC1 (Fibronectin Type III Domain Containing 1). FNDC1 is a member of the fibronectin type III domain family, which is characterized by the presence of fibronectin-like repeats. These repeats are involved in various protein-protein interactions that play a role in cellular processes such as signal transduction, structural organization, and cell adhesion. The inhibitors in this class are designed to modulate or suppress the activity of FNDC1, often by binding to its active sites or interfering with its ability to interact with other cellular proteins. By inhibiting FNDC1, these compounds can affect pathways or biological mechanisms in which this protein is a key mediator, potentially leading to alterations in processes such as cellular communication or the maintenance of cellular architecture.
Chemically, FNDC1 inhibitors can belong to various classes of molecules, including small organic compounds, peptides, or synthetic analogs designed to mimic specific binding patterns or motifs. The design of these inhibitors often involves detailed structural analyses of FNDC1 to identify active binding domains that are critical for its function. Once these domains are identified, inhibitors are synthesized to either compete for the same binding partners or disrupt the structural integrity of the protein. This inhibition can lead to downstream effects on signaling cascades or protein assemblies that FNDC1 is involved in. In some cases, these compounds are fine-tuned to achieve selective inhibition of FNDC1 over other related proteins, ensuring that off-target effects are minimized.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $89.00 $262.00 | 13 | |
Inhibits myosin light chain kinase. If FNDC1 interacts with actin-cytoskeleton dynamics, ML7 can be of relevance. | ||||||
Calpeptin | 117591-20-5 | sc-202516 sc-202516A | 10 mg 50 mg | $119.00 $447.00 | 28 | |
Calpain inhibitor. If FNDC1 undergoes calpain-mediated proteolysis, this inhibitor can affect its turnover. | ||||||
KN-62 | 127191-97-3 | sc-3560 | 1 mg | $133.00 | 20 | |
CaM kinase II inhibitor. Relevant if FNDC1 has functional intersections with Ca2+-mediated signaling. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $103.00 $293.00 $465.00 | 15 | |
Protein kinase C inhibitor. Could impact FNDC1 if it's involved in pathways mediated by PKC. | ||||||
Anacardic Acid | 16611-84-0 | sc-202463 sc-202463A | 5 mg 25 mg | $100.00 $200.00 | 13 | |
Histone acetyltransferase inhibitor. If FNDC1's function is regulated by acetylation, this compound could influence its activity. | ||||||
EX 527 | 49843-98-3 | sc-203044 | 5 mg | $85.00 | 32 | |
Sirtuin-1 inhibitor. Relevant if FNDC1 undergoes deacetylation by SIRT1, impacting its function or stability. | ||||||
A-443654 | 552325-16-3 | sc-507339 | 1 mg | $140.00 | ||
AKT inhibitor. If FNDC1 interacts or is involved in pathways mediated by AKT signaling, its activity might be influenced. | ||||||
INK 128 | 1224844-38-5 | sc-364511 sc-364511A | 5 mg 50 mg | $315.00 $1799.00 | ||
mTOR inhibitor. If FNDC1's function or expression is influenced by mTOR, this inhibitor can modulate its activity. | ||||||
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $180.00 $726.00 $1055.00 $3350.00 $5200.00 | 23 | |
AMPK activator. If FNDC1 operates within or parallel to the AMPK pathway, its activity might be influenced. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $134.00 $215.00 $440.00 $496.00 | 19 | |
A potent, irreversible proteasome inhibitor. If FNDC1 is regulated by proteasomal degradation, this compound could stabilize it. | ||||||